Purple Biotech Ltd (PPBT)

Despegar.com Statistics

Total Valuation

Purple Biotech has a market cap or net worth of $6.63 million. The enterprise value is $879,840.

Market Cap	6.63M
Enterprise Value	879,840

Important Dates

The last earnings date was Wednesday, August 6, 2025, before market open.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Purple Biotech has 547.24 million shares outstanding. The number of shares has increased by 82.76% in one year.

Current Share Class	n/a
Shares Outstanding	547.24M
Shares Change (YoY)	+82.76%
Shares Change (QoQ)	+3.95%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	599.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.21
P/TBV Ratio	1.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.00.

Current Ratio	2.88
Quick Ratio	2.70
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -8.56% and return on invested capital (ROIC) is -11.71%.

Return on Equity (ROE)	-8.56%
Return on Assets (ROA)	-10.27%
Return on Invested Capital (ROIC)	-11.71%
Return on Capital Employed (ROCE)	-17.99%
Revenue Per Employee	n/a
Profits Per Employee	-$290,111
Employee Count	9
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.22% in the last 52 weeks. The beta is -0.58, so Purple Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.58
52-Week Price Change	-69.22%
50-Day Moving Average	2.42
200-Day Moving Average	2.94
Relative Strength Index (RSI)	44.81
Average Volume (20 Days)	269,152

Short Selling Information

Short Interest	158,226
Short Previous Month	132,633
Short % of Shares Out	5.14%
Short % of Float	n/a
Short Ratio (days to cover)	7.03

Income Statement

Revenue	n/a
Gross Profit	-62,000
Operating Income	-5.79M
Pretax Income	18.76M
Net Income	-2.61M
EBITDA	-5.76M
EBIT	-5.79M
Earnings Per Share (EPS)	-$0.01

Balance Sheet

The company has $5.92 million in cash and $103,000 in debt, giving a net cash position of $5.82 million or $0.01 per share.

Cash & Cash Equivalents	5.92M
Total Debt	103,000
Net Cash	5.82M
Net Cash Per Share	$0.01
Equity (Book Value)	32.05M
Book Value Per Share	0.06
Working Capital	4.12M

Cash Flow

In the last 12 months, operating cash flow was -$8.83 million and capital expenditures -$2,000, giving a free cash flow of -$8.83 million.

Operating Cash Flow	-8.83M
Capital Expenditures	-2,000
Free Cash Flow	-8.83M
FCF Per Share	-$0.02

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-82.76%
Shareholder Yield	-82.76%
Earnings Yield	-39.40%
FCF Yield	-133.31%

Analyst Forecast

The average price target for Purple Biotech is $33.00, which is 1,379.82% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$33.00
Price Target Difference	1,379.82%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 17, 2024. It was a reverse split with a ratio of 1:20.

Last Split Date	Sep 17, 2024
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	1